

History of diabetes may delay antibiotic administration in patients with severe sepsis presenting to emergency departments

Toshikazu Abe, MD, MPH, PhD^{a,b,*}, Tomoharu Suzuki, MD^c, Shigeki Kushimoto, MD, PhD^d, Seitaro Fujishima, MD, PhD^e, Takehiro Sugiyama, MD, MSHS, PhD^{b,f}, Masao Iwagami, MD, PhD^b, Hiroshi Ogura, MD, PhD^g, Atsushi Shiraishi, MD, PhDⁿ, Daizoh Saitoh, MD, PhD^j, Toshihiko Mayumi, MD, PhD^l, Hiroki Iriyama, MD^a, Akira Komori, MD^a, Taka-aki Nakada, MD, PhD^k, Yasukazu Shiino, MD^l, Takehiko Tarui, MD, PhD^m, Toru Hifumi, MD, PhDⁿ, Yasuhiro Otomo, MD, PhD^o, Kohji Okamoto, MD, PhD^p, Yutaka Umemura, MD, PhD^q, Joji Kotani, MD, PhD^q, Yuichiro Sakamoto, MD, PhD^r, Junichi Sasaki, MD, PhD^s, Shin-ichiro Shiraishi, MD, PhD^t, Ryosuke Tsuruta, MD, PhD^u, Akiyoshi Hagiwara, MD, PhD^v, Kazuma Yamakawa, MD, PhD^w, Kiyotsugu Takuma, MD, PhD^x, Tomohiko Masuno, MD, PhD^y, Naoshi Takeyama, MD, PhD^z, Norio Yamashita, MD, PhD^{aa}, Hiroto Ikeda, MD, PhD^{ab}, Masashi Ueyama, MD, PhD^{ac}, Satoshi Gando, MD, PhD^{ad,ae}, for JAAM FORECAST group

Abstract

Clinical manifestations of sepsis differ between patients with and without diabetes mellitus (DM), and these differences could influence the clinical behaviors of medical staff. Therefore, we aimed to investigate whether pre-existing DM was associated with the time to antibiotics or sepsis care protocols.

This was a retrospective cohort study.

It conducted at 53 intensive care units (ICUs) in Japan.

Consecutive adult patients with severe sepsis admitted directly to ICUs from emergency departments from January 2016 to March 2017 were included.

The primary outcome was time to antibiotics.

Of the 619 eligible patients, 142 had DM and 477 did not have DM. The median times (interquartile ranges) to antibiotics in patients with and without DM were 103 minutes (60–180 minutes) and 86 minutes (45–155 minutes), respectively ($P = .05$). There were no significant differences in the rates of compliance with sepsis protocols or with patient-centred outcomes such as in-hospital mortality.

Editor: Babak Abdinia.

^a Department of General Medicine, Juntendo University, Tokyo, ^b Health Services Research and Development Center, University of Tsukuba, Tsukuba, ^c Department of General Medicine, Urasoe General Hospital, Urasoe, ^d Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Sendai, ^e Center for General Medicine Education, Keio University School of Medicine, ^f Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo, ^g Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka, ^h Emergency and Trauma Center, Kameda Medical Center, Kamogawa, ⁱ Division of Traumatology, Research Institute, National Defense Medical College, Tokorozawa, ^j Department of Emergency Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, ^k Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, ^l Department of Acute Medicine, Kawasaki Medical School, Kurashiki, Japan, ^m Department of Trauma and Critical Care Medicine, Kyorin University School of Medicine, ⁿ Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, ^o Trauma and Acute Critical Care Center, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan, ^p Department of Surgery, Center for Gastroenterology and Liver Disease, Kitakyushu City Yahata Hospital, Kitakyushu, ^q Division of Disaster and Emergency Medicine, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, ^r Emergency and Critical Care Medicine, Saga University Hospital, Saga, ^s Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, ^t Department of Emergency and Critical Care Medicine, Aizu Chuo Hospital, Aizuwakamatsu, ^u Advanced Medical Emergency & Critical Care Center, Yamaguchi University Hospital, Ube, ^v Department of Emergency Medicine, Niizashiki Chuo General Hospital, ^w Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, ^x Emergency & Critical Care Center, Kawasaki Municipal Kawasaki Hospital, Kawasaki, ^y Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo, ^z Advanced Critical Care Center, Aichi Medical University Hospital, Nagakute, ^{aa} Advanced Emergency Medical Service Center, Kurume University Hospital, Kurume, ^{ab} Department of Emergency Medicine, Teikyo University School of Medicine, Tokyo, ^{ac} Department of Trauma, Critical Care Medicine, and Burn Center Community Healthcare Organization, Chukyo Hospital, Nagoya, ^{ad} Division of Acute and Critical Care Medicine, Hokkaido University Graduate School of Medicine, ^{ae} Department of Acute and Critical Care Medicine, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.

* Correspondence: Toshikazu Abe, Department of General Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan (e-mail: abetoshi111@gmail.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Abe T, Suzuki T, Kushimoto S, Fujishima S, Sugiyama T, Iwagami M, Ogura H, Shiraishi A, Saitoh D, Mayumi T, Iriyama H, Komori A, Nakada T, Shiino Y, Tarui T, Hifumi T, Otomo Y, Okamoto K, Umemura Y, Kotani J, Sakamoto Y, Sasaki J, Shiraishi S, Tsuruta R, Hagiwara A, Yamakawa K, Takuma K, Masuno T, Takeyama N, Yamashita N, Ikeda H, Ueyama M, Gando S. History of diabetes may delay antibiotic administration in patients with severe sepsis presenting to emergency departments. *Medicine* 2020;99:11(e19446).

Received: 26 December 2019 / Received in final form: 21 January 2020 / Accepted: 7 February 2020

<http://dx.doi.org/10.1097/MD.00000000000019446>

The mortality rates of patients with and without DM were 23.9% and 21.6%, respectively ($P = .55$). Comparing patients with and without DM, the gamma generalized linear model-adjusted relative difference indicated that patients with DM had a delay to starting antibiotics of 26.5% (95% confidence intervals (95%CI): 4.6–52.8, $P = .02$). The gamma generalized linear model-adjusted relative difference with multiple imputation for missing data of sequential organ failure assessment was 19.9% (95%CI: 1.0–42.3, $P = .04$). The linear regression model-adjusted beta coefficient indicated that patients with DM had a delay to starting antibiotics of 29.2 minutes (95%CI: 6.8–51.7, $P = .01$). Logistic regression modelling showed that pre-existing DM was not associated with in-hospital mortality (odds ratio, 1.26; 95%CI: 0.72–2.19, $P = .42$).

Pre-existing DM was associated with delayed antibiotic administration among patients with severe sepsis or septic shock; however, patient-centred outcomes and compliance with sepsis care protocols were comparable.

Abbreviations: CCI = Charlson Comorbidity Index, DM = diabetes mellitus, ED = emergency department, FORECAST = Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis, and Trauma, ICUs = intensive care units, JAAM = Japanese Association for Acute Medicine, SOFA = sequential organ failure assessment, VFDs = ventilator-free days.

Keywords: bundle, comorbidity, diabetes mellitus, protocols, sepsis

1. Introduction

Diabetes mellitus (DM) is one of the most common comorbidities in the world. Although it is known to increase the likelihood of

infectious complications, including sepsis,^[1] its influence on patient-centred outcomes in patients who develop sepsis remains unclear.^[2–4] The complexities of DM in older patients with comorbidities who develop acute infection can make it difficult to

This study was supported by the Japanese Association for Acute Medicine (2014–01).

The study protocol was reviewed and approved by the ethics committees at all institutions that participated in the JAAM FORECAST group. These committees waived the need for written informed consent from the participants because of the retrospective and anonymized nature of the study. Institutional Review Board approval (No. 014–0306) was granted by Hokkaido University, the lead institution for FORECAST group. All methods were implemented in accordance with relevant guidelines and regulations.

Not commissioned; externally peer reviewed.

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

JAAM FORECAST Group

Osamu Tasaki³², Yasumitsu Mizobata³³, Hiraku Funakoshi³⁴, Toshiro Okuyama³⁵, Iwao Yamashita³⁶, Toshio Kanai³⁷, Yasuo Yamada³⁸, Mayuki Aibiki³⁹, Keiji Sato⁴⁰, Susumu Yamashita^{41,42}, Kenichi Yoshida⁴³, Shunji Kasaoka⁴⁴, Akihide Kon⁴⁵, Hiroshi Rinka⁴⁶, Hiroshi Kato⁴⁷, Hiroshi Okudera⁴⁸, Eichi Narimatsu⁴⁹, Toshifumi Fujiwara⁵⁰, Manabu Sugita⁵¹, Yasuo Shichinohe⁵², Hajime Nakae⁵³, Ryouji Iiduka⁵⁴, Mitsunobu Nakamura⁵⁵, Yuji Murata⁵⁶, Yoshitake Sato⁵⁷, Hiroyasu Ishikura⁵⁸, Yasuhiro Myojo⁵⁹, Yasuyuki Tsujita⁶⁰, Kosaku Kinoshita⁶¹, Hiroyuki Yamaguchi⁶², Toshihiro Sakurai⁶³, Satoru Miyatake⁶⁴, Takao Saotome⁶⁵, Susumu Yasuda⁶⁶, Yasuaki Mizushima⁶⁷

³² Nagasaki University Hospital

³³ Osaka City University Hospital

³⁴ Tokyo Bay Urayasu Ichikawa Medical Center

³⁵ Aso Iizuka Hospital

³⁶ Tomei Atsugi Hospital

³⁷ Hiratsuka City Hospital

³⁸ National Hospital Organization Sendai Medical Center

³⁹ Ehime University Hospital

⁴⁰ Okayama University Hospital

⁴¹ Tokuyama Central Hospital

⁴² Fukuyama City Hospital

⁴³ JA Hiroshima General Hospital

⁴⁴ Kumamoto University Hospital

⁴⁵ Hachinohe City Hospital

⁴⁶ Osaka City General Hospital

⁴⁷ National Hospital Organization Disaster Medical Center

⁴⁸ University of Toyama

⁴⁹ Sapporo Medical University

⁵⁰ Okayama Saiseikai General Hospital

⁵¹ Juntendo University Nerima Hospital

⁵² National Hospital Organization Hokkaido Medical Center

⁵³ Akita University Hospital

⁵⁴ Japanese Red Cross Society Kyoto Daini Hospital

⁵⁵ Maebashi Red Cross Hospital

⁵⁶ Sendai City Hospital

⁵⁷ Subaru Health Insurance Society Ota Memorial Hospital

⁵⁸ Fukuoka University Hospital

⁵⁹ Ishikawa Prefectural Central Hospital

⁶⁰ Shiga University of Medical Science

⁶¹ Nihon University School of Medicine

⁶² Seirei Yokohama General Hospital

⁶³ National Hospital Organization Kumamoto Medical Center

⁶⁴ Saiseikai Utsunomiya Hospital

⁶⁵ National Hospital Organization Higashi-Ohmi General Medical Center

⁶⁶ National Hospital Organization Mito Medical Center

⁶⁷ Rinku General Medical Center.

identify the development of sepsis and to provide an accurate prognosis. Patients with DM are also known to have different patterns of sepsis and different clinical manifestations,^[5] even if outcomes do not differ to those in patients without DM. For example, the risk of sepsis and the resulting complications and prognosis in DM have been reported to vary with the underlying infection.^[5,6] Also, the incidence of acute kidney injury was reportedly higher in patients with DM than in those without DM who developed sepsis,^[3,4] whereas respiratory failure and acute respiratory distress syndrome were less likely.^[4]

The different clinical manifestations of sepsis in DM could influence the decision making of medical staff, and better understanding this problem may be a key to disentangling the complicated relationship between these diseases. If we can identify a potentially modifiable factor that is unique to patients with diabetes who present with sepsis, it would enable us to improve sepsis management for these patients. Therefore, we aimed to investigate whether pre-existing DM was associated with the time to antibiotics and the compliance rate of sepsis care protocols.

2. Methods

2.1. Design, setting, and participants

We conducted a secondary analysis of the sepsis cohort from the Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis, and Trauma (FORECAST) study in Japan.^[7] The FORECAST used a multicenter, prospective cohort of acutely ill patients from 59 intensive care units and was conducted between January 2016 and March 2017. In this research, we included adult patients (age ≥ 16 years) with severe sepsis based on 2003 Sepsis-2 criteria,^[8] and excluded those who ordered “do not attempt resuscitation” or those with post-cardiopulmonary arrest resuscitation status at the time of sepsis recognition. We only included patients admitted to intensive care units (ICUs) directly from emergency departments because this ensured that we got temporally accurate sequence of events, such as time to antibiotics and bundle compliance. Finally, we excluded patients if the time to antibiotics was unknown, if the time to antibiotics exceeded 720 minutes, or if data for in-hospital mortality were missing.

The study protocol was reviewed and approved by the ethics committee of all participant institutes in the Japanese Association for Acute Medicine (JAAM) FORECAST group, Japan (IRB No.014–0306 on Hokkaido University, the representative for FORECAST group). This study followed the principles of the Declaration of Helsinki and was approved by the Ethics Committees of Osaka University Hospital. The ethics committee waived the need for informed consent because of the anonymous and retrospective nature of this study.

2.2. Data collection

Data were obtained from the FORECAST database, which was compiled from routine clinical records by the FORECAST investigators during the patient’s original hospital stay. The exposure variable of primary interest was the presence of DM in the medical history. Other variables included the patients’ demographic data, admission sources, comorbidities (Charlson Comorbidity Index; CCI), activities of daily living, organ dysfunction scores, infection characteristics, laboratory data, and blood culture results. In addition, we obtained data on

compliance with established sepsis care protocols, such as the measurement of serum lactate levels within 3 hours,^[9] and recorded the time to antibiotics. Time to antibiotics was the primary outcome, but secondary patient-centred outcomes were also assessed, including in-hospital mortality, length of stay, ICU-free days, and ventilator-free days (VFDs).

2.3. Data definitions

Time zero for the start times of antibiotics or bundle compliance was when a physician recognised severe sepsis or septic shock. Time to antibiotics was the time at which antibiotics were first administered. History of DM was derived from CCI. The modified CCI was calculated without including DM. Septic shock and organ dysfunction were defined according to the Sepsis-2 criteria.^[8] Suspected sites of infection in the FORECAST database initially included 11 foci: lung, intra-abdominal, urinary tract, soft tissue, wound, osteo-articular, endocardium, catheter-related, implant device-related, central nervous system, and undifferentiated. However, the number of patients in some categories was small, so these were consolidated into 7 main clinical categories: lung, intra-abdominal, urinary tract, soft tissue (soft tissue and wound), bloodstream-related (osteo-articular, endocardial, catheter-related, and implant device-related), central nervous system, and undifferentiated. VFD was defined as the number of days within the first 28 days after enrolment during which a patient was able to breathe without the help of a ventilator. VFD of patients who died during the study period was assigned as 0. ICU-free days were similarly calculated.^[10]

2.4. Analysis

Descriptive statistics are presented as counts (proportions) for categorical variables and medians (interquartile ranges) or means \pm standard deviations for continuous variables, as appropriate.

First, we compared baseline patient characteristics and demographic data, infection characteristics, organ dysfunction, and sepsis severity scores between patients with and without DM. Time to antibiotics is displayed using kernel density plots after comparing patients with and without DM. We also compared compliance with sepsis care protocols as well as the patient-centred outcomes between the groups. The analyses were repeated to compare patients with DM-related complications, DM alone, and no DM.

Next, we developed regression models to evaluate whether pre-existing DM was associated with delayed antibiotic administration, using generalized linear models with log-link functions to account for the right-skewed distributions. The results of the Park test^[11] indicated a γ -distribution to be most appropriate for our data. Age, CCI (excluding DM), suspected infection site, and sequential organ failure assessment (SOFA) score were used for adjustment based on previous reports of their clinical importance (chosen a priori). We also carefully checked for interactions between DM and the CCI (excluding DM) and assessed each variable for multi-collinearity. We then reported the adjusted relative difference for the time to antibiotics. An additional analysis of patients with and without DM-related complications was performed and reported for all 3 groups (i.e., DM-related complications, DM alone, and no DM), using the same covariates for adjustment. Finally, we performed logistic regression analysis to evaluate the relationship between in-hospital mortality and a

history of pre-existing DM. Age, CCI (excluding DM), suspected site of infection, and the SOFA score were used for adjustment. These analyses are reported with their 95% confidence intervals (95% CIs).

2.5. Sensitivity analysis

Because 20% data of SOFA score, which is one of the most important variables in sepsis, was missing, we performed another sensitivity analysis by multiple imputations to handle missing data of SOFA. Supplemental Table 1 (Additional file 1, <http://links.lww.com/MD/D917>) shows characteristics of patients with and without missing data of SOFA. To impute the missing data, we constructed multiple ordered logistic regression models, including variables potentially related to the fact that the data were missing, those correlated with that outcome and those that had less missing data. The results across 20 imputed data sets were combined by averaging and standard errors were adjusted to reflect within-imputation and between-imputation variabilities.

Moreover, we used linear regression model for primary analysis as another sensitivity analysis because the results of the gamma generalized linear model were difficult to interpret. The same variables used in as the primary analysis were used.

All *P*-values were two-sided, with values of $<.05$ considered statistically significant. Statistical analyses were performed with Stata software, version 15.1 (StataCorp, TX).

3. Results

Of 676 patients with severe sepsis at the time of ICU admission from the emergency department (ED), we excluded 57 (8.4%) who did not meet our inclusion criteria or who had missing data. Of the remaining 619 patients from 53 ICUs, 142 had DM, and 477 did not (Supplemental Figure 1, <http://links.lww.com/MD/D916>). Baseline characteristics, comorbidities, organ failure, APACHE II scores, and SOFA scores were comparable between the groups with and without DM (Table 1).

However, patients with DM had fewer abdominal infections, more soft tissue infections, and higher C-reactive protein and procalcitonin levels than their peers without DM (all $P < .01$). Supplemental Table 2 (Additional file 2, <http://links.lww.com/MD/D918>) shows characteristics of patients with sepsis categorized into those with DM-related complications, those without DM-related complications and those without DM.

Overall, the median time to antibiotics was 89 minutes (47–160 minutes), with median times of 103 minutes (60–180 minutes) for patients with DM, and 86 minutes (45–155 minutes) for patients without DM ($P = .05$) (Fig. 1). After stratifying patients with DM by the presence ($n = 35$) or absence ($n = 107$) of complications, the median times to antibiotics were 119 minutes (63–180 minutes) and 98 minutes (52–180 minutes), respectively, compared with 86 minutes (45–155 minutes) ($P = .14$) in those without DM. There was no significant difference in compliance with sepsis protocols between the groups with and without DM (Table 2), even after stratification for the presence or absence of DM-related complications (Supplemental Table 3: Additional file 3, <http://links.lww.com/MD/D919>).

The crude mortality was 22.1%, with mortality rates of 23.9% and 21.6% in patients with and without DM, respectively ($P = .55$) (Table 3). The mortality rates among patients with DM-related complications, without DM-related complications, and

without DM were 31.4%, 21.5%, and 21.6%, respectively ($P = .39$) (Supplemental Table 4: Additional file 4, <http://links.lww.com/MD/D920>). Additional file 4 shows outcomes among patients with sepsis categorized into those with DM-related complications, those without DM-related complications and those without DM. In addition, there were no significant differences in patient-centred outcomes, such as the length of hospital stay, between patients with and without DM (Table 3).

The gamma generalized linear model-adjusted relative difference for the time to antibiotics showed that the DM group had a 26.5% delay (95% CI: 4.6–52.8; $P = .02$) in receiving antibiotics when compared with the group that had no history of DM (Table 4). The gamma generalized linear model-adjusted relative difference with multiple imputation for missing data of SOFA was 19.9% delay (95% CI: 1.0–42.3, $P = .04$). The linear regression model-adjusted beta coefficient indicated that patients with DM had a delay to starting antibiotics of 29.2 minutes (95% CI: 6.8–51.7, $P = .01$). The linear regression model-adjusted beta coefficient with multiple imputation for missing data of SOFA was 22.0 minutes delay (95% CI: 1.8–42.3, $P = .03$). After stratifying the DM group into those with and without complications, antibiotic administration was delayed in the latter (relative difference [95% CI]: 26.7% [1.8%–56.8%]; $P = .03$) but not in the former (relative difference [95% CI]: 26.7% [–8.8 to 76.2]; $P = .16$) relative to patients without DM (Table 4). The logistic regression model showed that a history of pre-existing DM was not associated with in-hospital mortality among patients with severe sepsis or septic shock (odds ratio, 1.26; 95% confidence interval, 0.72–2.19, $P = .42$) (Table 5).

4. Discussion

4.1. Summary

We performed secondary analyses of patients with severe sepsis and septic shock using data from a multicentre prospective cohort study in Japan. Our results show that pre-existing DM was related to delayed antibiotic administration among these patients. By contrast, patient-centred outcomes and compliance with sepsis care protocols were comparable between patients with and without DM.

Limited information exists about personal factors related to delays in the delivery of sepsis care protocols. To date, most studies have reported varied results when looking into the socioeconomic factors or systems that delay or block access,^[12–15] including our previous research.^[7] In the present study, however, we found that personal factors may be related to treatment delays. Therefore, we may need to consider not only improvements to systems but also to the identification of those who need special attention in the management of sepsis.

A small delay of 17 minutes in the median time to start antibiotics (103 and 83 minutes with and without DM, respectively; 26.5% delay by the gamma generalized linear model adjustment; 29.2 minutes delay by the linear regression model) may be important, considering recent bundle guidance recommends starting antibiotics within 1 hour.^[16] On the other hand, it has been still controversial the relationship between mortality and time to antibiotics as well as our other secondary analysis which included all patients with sepsis (from EDs, wards, and inside ICUs) in the FORECAST study.^[17] There was no significant difference in patient-centred outcomes according to time to antibiotics in this study, either. Since the protocols on

Table 1**Characteristics of patients with sepsis according to the presence or absence of DM (n=619).**

Characteristics		DM (n = 142)	No DM (n = 477)	P-value	
Age, yr	At admission	74 (66–81)	76 (66–83)	.18	
Male		83 (58.5)	288 (60.4)	.68	
BMI, kg/m ²		22.6 ± 4.6	21.6 ± 4.8	.05	
Coexisting conditions	Myocardial infarction	8 (5.6)	17 (3.7)	.27	
	Congestive heart failure	15 (10.6)	45 (9.4)	.69	
	Peripheral vascular disease	4 (2.8)	9 (1.9)	.50	
	Cerebrovascular disease	19 (13.4)	58 (12.2)	.70	
	Dementia	14 (9.9)	53 (11.1)	.67	
	COPD	8 (5.6)	41 (8.6)	.25	
	Connective tissue disease	6 (4.2)	27 (5.7)	.50	
	Peptic ulcer disease	4 (2.8)	17 (3.6)	.67	
	Chronic kidney disease	13 (9.2)	27 (5.7)	.14	
	Hemiplegia	5 (3.5)	18 (3.8)	.89	
	Malignancy (solid)	14 (9.9)	64 (13.4)	.26	
	Malignancy (leukemia)	0 (0)	3 (0.6)	.34	
	Malignancy (lymphoma)	2 (1.4)	3 (0.6)	.36	
	Metastatic tumour	1 (0.7)	6 (1.3)	.58	
	Mild liver disease	5 (3.5)	19 (4.0)	.80	
	Moderate to severe liver disease	1 (0.7)	12 (2.5)	.19	
	AIDS	0 (0)	1 (0.2)	.59	
	Medication	Immunosuppressant	3 (2.1%)	10 (2.1%)	.991
		Steroid	14 (9.9%)	47 (9.9%)	.998
	Non-diabetic CCI		1 (0–2)	1 (0–2)	.32
ADL	Dependent	36 (25.4)	124 (26.1)	.87	
Suspected infection site	Lung (n = 209)	52 (36.6)	157 (32.9)	.41	
	Abdomen (n = 138)	19 (13.4)	119 (24.9)	<.01	
	Urinary tract (n = 138)	31 (21.8)	107 (22.4)	.88	
	Soft tissue (n = 63)	24 (16.9)	39 (8.2)	<.01	
	Central nervous system (n = 11)	3 (2.1)	8 (1.7)	.73	
	Blood stream-related (n = 29)	6 (4.2)	23 (4.8)	.77	
	Others (n = 31)	7 (4.9)	24 (5.0)	.96	
	Vital signs	Systolic BP (mm Hg)	107 (84–131)	97 (80–124)	.05
	Pulse rate (beats/min)	112 ± 26	113 ± 25	.72	
	Respiratory rate (breaths/min)	24 (21–30)	26.5 (23–31)	.01	
	Body temperature (Celsius)	37.5 (36.5–38.9)	37.8 (36.6–38.8)	.42	
	Consciousness (GCS)	14 (9–15)	14 (9.5–15)	.85	
Fever (body temperature ≥37.0)		91 (64.1)	334 (70.0)	.18	
qSOFA ≥ 2		94 (66.7)	341 (74.6)	.29	
Bacteraemia		89 (69.0)	269 (60.9)	.19	
Septic shock	Yes	84 (59.2)	289 (60.6)	.76	
Organ dysfunction on arrival	Hyperlactatemia (>2 mmol/L)	104 (73.2)	351 (73.6)	.93	
	Acute kidney injury (Cre > 2 mg/dL)	59 (41.5)	171 (35.8)	.22	
	Hyperbilirubinemia (>2.0 mg/dL)	22 (15.5)	88 (18.4)	.42	
	Thrombocytopenia (<100,000/μL)	39 (27.5)	113 (23.7)	.36	
	Coagulopathy (PT INR > 1.5)	18 (12.7)	80 (16.8)	.24	
	ARDS at arrival*		21 (17.2)	78 (18.4)	.77
Mechanical ventilation		53 (39.0)	160 (34.6)	.35	
APACHE II score		23 (16–29)	22 (17–29)	.76	
SOFA score		8 (6–11)	9 (6–11)	.62	
Laboratory data at ED	White blood cell count (10 ³ cells/μL)	12.6 (6.6–18.6)	10.9 (5.9–18.0)	.22	
	WBC differentials, band (%)	2 (0–31.5)	7 (0–35.5)	.40	
	Hematocrit (%)	34.9 ± 7.4	35.7 ± 7.5	.26	
	Total protein (g/dL)	5.9 ± 1.0	6.1 ± 1.0	.09	
	Albumin (g/dL)	2.8 ± 0.7	2.9 ± 0.7	.09	
	Lactate (mmol/L)	3.3 (2–5.6)	3.7 (2.1–5.9)	.13	
	C-reactive protein (mg/dL)	17.4 (8.3–27.9)	14.1 (5.2–23.6)	.01	
	Procalcitonin (ng/mL)	23.5 (1.9–90.2)	8.3 (1.7–37.7)	.04	
	Serum glucose (g/dL)	202 (136–289)	130 (103–168)	<.01	

Reported counts (proportions) for categorical variables and median (interquartile range) or mean ± standard deviation (SD) for continuous variables, where appropriate. *Missing data:* BMI = 17; ADL = 1; bacteraemia = 1; systolic BP = 17; pulse rate = 1; respiratory rate = 1; body temperature = 21; consciousness = 5; bacteraemia = 48; ARDS = 73; mechanical ventilation = 21; APACHE II score = 94; SOFA score = 125; white blood cell count = 2; WBC differentials = 423; hematocrit = 2; total protein = 26; albumin = 14; lactate = 17; C-reactive protein = 7; procalcitonin = 305; serum glucose = 9. ADL = activities of daily living, AIDS = acquired immune deficiency syndrome, APACHE = acute physiology and chronic health evaluation, ARDS = acute respiratory distress syndrome, BMI = body mass index, BP = blood pressure, CCI = Charlson Comorbidity Index, COPD = chronic obstructive pulmonary disease, Cre = creatinine, DM = diabetes mellitus, GCS = Glasgow coma scale, IV = intravenous, SOFA = sequential organ failure assessment.

* ARDS was defined by Berlin criteria.




Figure 1. Kernel density plot for the time to first antibiotic administration from the emergency department. The distributions for patients with and without DM are shown by solid and a dashed line, respectively. DM=diabetes mellitus.

Table 2
Compliance with sepsis care protocols among patients with sepsis according to the presence or absence of DM (n=619).

Applicable elements of the sepsis bundle	Compliance rate		P-value
	DM	No DM	
Entire 3-h resuscitation bundle*	70 (70.7)	253 (71.7)	.85
P1. Serum lactate obtained	138 (97.2)	464 (97.5)	.85
P2. Broad-spectrum antibiotic given	130 (91.5)	413 (86.9)	.14
P3. Blood cultures obtained before broad-spectrum antibiotic administration	137 (96.5)	455 (96.0)	.79
P4. 30 mg/kg crystalloid fluid bolus delivered (yes/cases with indication)*	76 (76.8)	293 (82.8)	.17
Other sepsis care protocols			
P5. Vasopressors use followed initial fluid bolus if needed to maintain MAP ≥ 65 mm Hg (yes/cases with indication)	83 (81.4)	285 (87.2)	.14
P6. Re-measured lactate if initial lactate elevated (yes/cases with indication)	98 (88.3)	346 (89.4)	.74

Data are reported as counts (proportions).
* Septic shock or lactate > 4 mmol/L. Missing data: P1 = 1; P2 = 2; P3 = 3; P4 = 5; P5 = 3; P6 = 4. Number of cases with indication for P4, P5, and P6: P4 = 453; P5 = 437; P6 = 498. DM = diabetes mellitus, MAP = mean arterial pressure.

Table 3
Outcomes among patients with sepsis according to the presence or absence of DM (n=619).

Outcomes	DM (n=142)	No DM (n=477)	P-value
In-hospital mortality	34 (23.9)	103 (21.6)	.55
With shock (n=373)	26 (31.0)	77 (26.6)	.44
Without shock (n=246)	8 (13.8)	26 (13.8)	.99
Survivor dispositions	46 (42.6)	155 (41.4)	.83
Home (vs transfer)	20 (12–25)	21 (12–25)	.59
ICU-free days	21 (0–28)	22 (0–28)	.59
Ventilator-free days	22 (12–36)	21 (11–37)	.69

Data are reported as counts (proportions) for categorical data and as medians (interquartile ranges) for continuous variables. Missing data: Survivor dispositions = 137; ICU-free days = 126; ventilator-free days = 9. DM = diabetes mellitus, ICU = intensive care unit.

Table 4
Model-adjusted relative difference in time to antibiotics among septic patients with DM (1. total, and 2. stratified by DM complications) with reference to those without DM (n=494).

		Relative difference (%)	95%CI	P-value	
1. Total (multiple imputation model for missing data of SOFA)	DM (ref. non-DM)	26.5	4.6	52.8	.02
	DM (ref. non-DM)	19.9	1.0	42.3	.04
2. Stratified	Non-DM		Reference		
	DM with complications	26.7	-8.8	76.2	.16
	DM without complications	26.4	1.8	56.8	.03

Adjusted for age CCI without DM, SOFA score, infection site (lung, abdomen, urinary tract, soft tissue, blood stream-related CNS, and others) by the gamma generalized linear model. CCI=Charlson Comorbidity Index, CNS=central nervous system, DM=diabetes mellitus, SOFA=sequential organ failure assessment.

resuscitation, such as fluid bolus delivered and vasopressor use are a trigger for vital signs, it is naturally not related to the history of DM. We expected that protocols related to infection, such as the rate of blood culture and broad-spectrum antibiotics would decline; however, the median of time to antibiotics was 103 minutes and 86 minutes, and considering the rate of blood culture was about 90% or more in our study,^[7] it was not a comparison that could show a significant difference within 3 hours protocol. However, further studies are required in this topic.

Notably, there was no statistical significance in sepsis care, such as time to antibiotics and bundles when patients with DM were stratified by the presence or absence of complications. The study may have been underpowered to show such differences because of the small number of patients with DM-related complications. However, similar model-adjusted relative differences in time to antibiotics imply that the delay in starting antibiotics and the prognosis of septic patients with DM were not affected by these complications.

Our study might be underpowered to detect the effect of diabetes on mortality. A previous report indicated that glucose variability, and not pre-existing DM, is independently associated with in-hospital mortality for patients with sepsis.^[18,19] This suggests that the management of glucose level of a patient is more important than considering it as comorbidity.

We were not able to investigate the mechanism of the observed association between diabetes and antibiotic timing from our results. Diabetic patients seemed to have slightly less derangement of some vital signs, which may have reduced the urgency that clinicians felt when initiating antibiotics after sepsis recognition. We believe that both systemic and local host factors

contributed. For example, DM has typically been associated with specific infection sites, such as the skin and soft tissue,^[5] and it is known that patients with DM are more susceptible to particular infections. Presumably, hyperglycemia-related impairment of the immune response may influence the development of infection and the resulting unmeasured clinical features, such as vague presentations.^[20] Further studies are needed to investigate the relationship between clinical features, the causative organisms, and the immune response, and how these interact to delay treatment among patients with DM.

Moreover, patients with diabetes may have lower threshold to meet sepsis criteria with less severe illness. Although clinicians will have experienced that DM is associated with severe infection and worse outcomes, our results did not show a difference in mortality between patients with and without DM. The Sepsis-2 criteria, which we used as an inclusion criterion, cannot distinguish acute from chronic organ failure, and severity scores were similar between patients with and without DM in our cohort. We clinically presumed that patients with DM had more chronic organ failures than those without DM regardless of CCI. Thus, the DM cohort might also have included those with less severe sepsis or pseudo-sepsis if pre-existing organ failures were considered sepsis-related, and this could have affected the mortality rate. Given that patients with DM received antibiotics for sepsis after a delay, their clinical course might have been affected and have altered our clinical impressions. Severe sepsis continues to be an underdiagnosed and undertreated condition (i.e., there is low bundle compliance), with its influence on mortality still debated.^[21] The contribution of DM to sepsis outcomes remains a major problem given that it is the most common major comorbidity.

Table 5
Logistic regression model for in-hospital mortality comparing patients with DM and those without DM (n=494).

		Odds ratio	95%CI	
DM		1.26	0.72	2.19
Age		1.02	1.00	1.04
CCI without DM		1.16	0.99	1.35
SOFA score		1.23	1.15	1.32
Infection site	Lung		Reference	
	Abdomen	0.71	0.38	1.34
	Urinary tract	0.63	0.32	1.25
	Soft tissue	0.90	0.38	2.15
	Blood stream-related	1.44	0.51	4.08
	CNS	7.76	1.76	34.27
	Others	1.27	0.46	3.46

CCI=Charlson Comorbidity Index, CNS=central nervous system, DM=diabetes mellitus, SOFA=sequential organ failure assessment.

4.2. Limitations

This study has several important limitations. First, the nature of the secondary study design meant that we could not make causal inferences between the observed characteristics and outcomes. Second, for the sepsis care protocols, we considered time zero to be the time of sepsis recognition instead of the time of arrival at the ED. Although previous reports have often used sepsis recognition as time zero, this approach may have caused bias.^[22] Third, the presence of disparities in the use and timing of sepsis care protocols between institutions cannot be excluded, although other sepsis care protocols were comparable between groups. Fourth, we could not separate patients with type 1 and type 2 DM, which may have affected the results.^[5] Fifth, we did not have specific data of immunity such as end stage renal disease although we have data of comorbidities which was deprived from CCI. Finally, in-hospital mortality data may have been optimistic

because we did not follow-up the kinds of facilities where the patients were transferred from study hospitals, although survivors are mainly transferred to skilled nursing facilities from acute care hospitals in Japan.

5. Conclusions

In conclusion, a history of DM was associated with delayed antibiotic administration in patients with severe sepsis and septic shock. However, compliance with sepsis care protocols was comparable. This study has important implications for the management of sepsis in patients with diabetes in Japan.

Acknowledgments

We would like to thank Enago (<https://www.enago.jp>) for the final English language editing. We also thank the JAAM FORECAST Group for its valuable contribution to this study.

Author contributions

All authors meet the ICMJE authorship criteria. TA contributed to the acquisition of data, conceived and designed this study, interpreted the data, drafted the manuscript, and revised the manuscript for important intellectual content. TS, HI, and AK contributed to the conceiving and designing this study, interpreted the data, and revised the manuscript for important intellectual content. AS contributed to the acquisition of data, conducted data cleaning, interpreted the data, and revised the manuscript for important intellectual content. SK, SG, and AH contributed to the acquisition of data, jointly conceived and designed this study, interpreted the data, and revised the manuscript for important intellectual content. All of the authors contributed to the acquisition of data, and reviewed, discussed, and approved the final manuscript.

Toshikazu Abe: 0000-0002-8343-5151.

Toshikazu Abe orcid: 0000-0002-8343-5151.

References

- [1] Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clin Infect Dis* 2005;41:281–8.
- [2] Schuetz P, Jones AE, Howell MD, et al. Diabetes is not associated with increased mortality in emergency department patients with sepsis. *Ann Emerg Med* 2011;58:438–44.
- [3] Wang Z, Ren J, Wang G, et al. Association between diabetes mellitus and outcomes of patients with sepsis: a meta-analysis. *Med Sci Monit* 2017;23:3546–55.
- [4] Esper AM, Moss M, Martin GS. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. *Crit Care* 2009;13:R18.
- [5] Carey IM, Critchley JA, DeWilde S, et al. Risk of infection in Type 1 and Type 2 diabetes compared with the general population: a matched cohort study. *Diabetes Care* 2018;41:513–21.
- [6] Sinapidis D, Kosmas V, Vittoros V, et al. Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection. *BMC Infect Dis* 2018;18:242.
- [7] Abe T, Ogura H, Shiraishi A, et al. Characteristics, management, and in-hospital mortality among patients with severe sepsis in intensive care units in Japan: the FORECAST study. *Crit Care* 2018;22:322.
- [8] Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med* 2003;31:1250–6.
- [9] Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med* 2013;41:580–637.
- [10] Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (awakening and breathing controlled trial): a randomised controlled trial. *Lancet* 2008;371:126–34.
- [11] Manning WG, Mullahy J. Estimating log models: to transform or not to transform? *J Health Econ* 2001;20:461–94.
- [12] Phua J, Koh Y, Du B, et al. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. *BMJ* 2011;342:d3245.
- [13] Kim JH, Hong SK, Kim KC, et al. Influence of full-time intensivist and the nurse-to-patient ratio on the implementation of severe sepsis bundles in Korean intensive care units. *J Crit Care* 2012;27:414e11–21.
- [14] Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. *JAMA* 1999;282:1458–65.
- [15] Damiani E, Donati A, Serafini G, et al. Effect of performance improvement programs on compliance with sepsis bundles and mortality: a systematic review and meta-analysis of observational studies. *PLoS One* 2015;10:e0125827.
- [16] Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. *Intensive Care Med* 2018.
- [17] Abe T, Kushimoto S, Tokuda Y, et al. Implementation of earlier antibiotic administration in patients with severe sepsis and septic shock in Japan: a descriptive analysis of a prospective observational study. *Crit Care* 2019;23:360.
- [18] Ali NA, O'Brien JMJr, Dungan K, et al. Glucose variability and mortality in patients with sepsis. *Crit Care Med* 2008;36:2316–21.
- [19] Pisarchik AN, Pochehen ON, Pisarchyk LA. Increasing blood glucose variability is a precursor of sepsis and mortality in burned patients. *PLoS One* 2012;7:e46582.
- [20] Filbin MR, Lynch J, Gillingham TD, et al. Presenting symptoms independently predict mortality in septic shock: importance of a previously unmeasured confounder. *Crit Care Med* 2018.
- [21] Deis AS, Whiles BB, Brown AR, et al. Three-hour bundle compliance and outcomes in patients with undiagnosed severe sepsis. *Chest* 2018;153:39–45.
- [22] Sterling SA, Miller WR, Pryor J, et al. The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: a systematic review and meta-analysis. *Crit Care Med* 2015;43:1907–15.